| 1/4 | US=23-A / Câncer Bartolazzi A. Non-small cell lung carcinoma: EGFR gene mutations and response to gefitinib. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods and overviews, lung carcinoma and prostate carcinoma. v.2. New York: Springer, 2008. p. 291-306. ISBN 978-1-4020-8441-62. CANCER; CANCER DE PULMAO; CANCER DE PULMAO DE NAO-PEQUENAS CELULAS; MUTACOES EGFR; GEFITINIBE; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO |
| 2/4 | US=23-A / Câncer Kiura K, Takigawa N, Segawa Y. Advanced non-small cell lung carcinoma: acquired resistance to gefitinib. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods and overviews, lung carcinoma and prostate carcinoma. v.2. New York: Springer, 2008. p. 307-16. ISBN 978-1-4020-8441-62. CANCER; CANCER DE PULMAO; CANCER DE PULMAO DE NAO-PEQUENAS CELULAS; CARCINOMA NAO PEQUENAS CELULAS DO PULMAO AVANCADA; RESISTENCIA A GEFITINIBE; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO |
| 3/4 | US=69 / Câncer Stewart DJ. Targeted therapy in non-small cell lung cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 125-56. ISBN 978-1-60327-423-4. TERAPIA-ALVO; NAO-PEQUENAS DE CANCER DE PULMAO DE CELULAS; EGFR; ERLOTINIB; GEFITINIB; VEGFR |
| 4/4 | US=92 / Biol/Mol Deininger M. Established cancer therapies: tyrosine kinase inhibitors. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 477-508. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9. TERAPIA-ALVO; BCR-ABL; FLT3; EGFR; TYROSISE INIBITORS QUINASE; IMATINIB; GEFITINIB; ERLOTINIB; CANCER; LEUCEMIA |